Posttraumatic stress disorder (PTSD) occurs in approximately 7% of adults in the general population. PTSD greatly impacts quality of life and often co-occurs with other conditions, such as chronic pain. Individuals with co-morbid PTSD and chronic pain demonstrate higher PTSD symptoms and pain (as well as greater anxiety, depression, disability, and opioid use) compared to those with only one of those conditions.

Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney failure. Treatments are available, but MM can come back (relapse) or may not get better (refractory) with treatment. This is a study to determine the safety, efficacy, and pharmacokinetics of Etentamig in adult participants with MM.
   

Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not be enough to control the AD in trial participants who require systemic anti-inflammatory treatment. This study aims to provide data on the efficacy and safety of upadacitinib at different doses in adult participants with moderate to severe AD.

Upadacitinib is an approved drug for the treatment of moderate to severe atopic dermatitis (AD).

This clinical trial is for men and women with newly diagnosed multiple myeloma who are not considered a candidate for high-dose chemotherapy with autologous stem cell transplant (ASCT).
   
The purpose of this study is to compare the efficacy of teclistamab in combination with daratumumab and lenalidomide (Tec-DR) and talquetamab in combination with daratumumab and lenalidomide (Tal-DR) versus daratumumab, lenalidomide, dexamethasone (DRd).
   

The purpose of this study is to test the safety of a drug called CA-4948 in combination with pembrolizumab for patients with metastatic urothelial cancer. This study tests different doses of the drug to determine the highest dose with manageable side effects in people.

This clinical trial is for adults who have been diagnosed with non-small cell lung cancer (NSCLC).

This clinical trial is for adults who have relapsed or refractory multiple myeloma (either their disease has come back, or it is no longer responding to their current treatment) and standard therapies available to treat their disease may have limited effectiveness.
   

The purpose of this study is to evaluate the safety and effectiveness of the Elevate System for patients needing non-emergent percutaneous coronary intervention (PCI).

The Elevate System is an investigational heart pump device, which means it has not been approved by the U.S. Food and Drug Administration (FDA). It is being compared with an already approved heart pump device called the Impella System. The Impella System is approved for patients having HR-PCI.

The purpose of this study is to evaluate the safety and efficacy of percutaneous endovascular catheter-facilitated intramyocardial delivery of XC001 in treating refractory angina compared to standard treatment.

The purpose of this study is to see if an experimental device, called the Shockwave Medical Inc. Reducer System (Reducer) is safe and useful in treating refractory angina compared to standard treatment.

Experimental means that the device is not approved by the U.S. Food and Drug Administration (FDA).